11.11.2017 | Ajankohtaista
Senior Scientists, Cell Biology – Orion corporation, Turku, Finland
Job description
Orion Corporation operates in more than 20 countries, where we Orionees, 3400 in total, work in all kinds of positions. Among us there are Research Scientists, Laboratory Technicians, Engineers and IT Specialists as well as people working in Production, just to mention some examples. We offer diverse and responsible jobs to our personnel in a truly multi-disciplinary work environment. We encourage people to develop their competences and offer opportunities to affect the job description and creating their own career path at Orion. We are searching for top talents who are ready to share our passion for the work that we do.
We are looking for two Senior Scientists (Cell Biology) who provide scientific and technological expertise for biologics and therapeutic antibody development in the laboratory.
The first role will focus on characterizing the molecular and cellular action of antibodies using advanced cell engineering and cell biological techniques.
The second role will focus on characterization of new therapeutic antibodies in laboratory and the work will include immunological assay setups and validation, as well as binding and functional studies, for example studying effector functions.
In both roles you will also be involved in choosing the optimal technology for antibody generation. Both Senior Scientists will spend time in the laboratory doing hands-on research, however part of the work is also done in cooperation with CROs (contract research organization).
Description of unit
Orion’s pharmaceutical innovations are created within its R&D organization, including non-clinical research and clinical development. The organization employs top professionals in the field of drug development. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs.
We have seen growth in R&D productivity over the last years and have now an exciting R&D pipeline. In order to ensure future development, we have started to build capabilities for biologics discovery. In addition we are strengthening our power in small molecule research. Experienced professionals with new competencies are needed to guarantee our continuous success.
The recently established Biologics function is part of our R&D organization and it is responsible for bringing forward our biologics pipeline. To fulfill this exciting task, the Biologics function is now recruiting several R&D experts with a track record of developing therapeutic antibodies. The function is new and you have a great opportunity to be part of developing its processes.
We offer
We offer exciting opportunities to create and have an impact on future therapies for patients.We also offer you attractive career development opportunities to use your own strengths for development. The culture of Orion R&D is informal and we enjoy working together.Join us – together we build well-being and do work that we are proud of!
The job is located in Turku, Finland. If you are located somewhere else in the world at the moment you might want to check the areas Finland is considered a leader in the world: http://www.huffingtonpost.com/ira-kalb/finland-is-still-the-worl_b_10774930.html
Requirements
For both roles we expect you to have a relevant PhD for example in Cell Biology, Molecular Biology or Biochemistry, with a strong track record of developing therapeutic antibodies. We value work experience in the pharmaceutical industry or a long academic career. We hope that you have contributed significantly in Microscopy (Immunofluorescence and/or High Content Imaging) and/or Flow cytometry experiments. We also hope that you have experience in working with partners.
In addition, for the first role we expect you to have thorough hands-on laboratory experience regarding molecular and cellular mechanisms of therapeutic antibodies. For the second role we expect you to have thorough hands-on experience of laboratory work related to antibody generation as well as mode of action studies.
We are looking for high influencers in their area of expertise. Taking independent responsibility even in new situations will lead to success in these positions. These jobs also require superb networking and negotiation skills. We also value high problem-solving skills, in-depth analytical thinking and a touch of creativity. Our main working language is English therefore we expect excellent English language skills.
To apply
We are passionate about patient welfare and we are The Voice of Science and the Patient – do you share the same values? Then please leave your application complemented with a salary request (Yearly Net Salary). You can also check our other positions in R&D at the moment https://www.orion.fi/ura-orionilla/.
Are you interested in hearing more? Please call Tim Holmström, Head of Biologics +358509667314, on Monday 13th of November at 16.00 – 17.00, or on Monday 20th of November at 16.00 – 17.00 (EET)
Approved medical examination which also includes drug testing is required prior to the employment, and we will carry out a security clearance prior to the employment for the selected person.
6.11.2017 | Ajankohtaista
6.11.2017 | Ajankohtaista
PhD position available in the field of autophagy at the Department of Biomedicine, University of Turku, Finland
Location: Department of Biomedicine, University of Turku, Turku, Finland
Supervisor: Prof. Eeva-Liisa Eskelinen
Length of appointment: 4 years
Indicative Starting date: May 2018
Type of Contract: temporary
Hours per week: 36 (full time)
Description: The PhD position is part of a collaborative project, DRIVE (Driving next generation autophagy researchers towards translation). DRIVE is a Marie Skłodowska-Curie Action (MSCA) Innovative Training Network (ITN) H2020-MSCA-ITN-2017, funded by the European Commission under Grant Agreement number 765912. More information on the DRIVE consortium: https://drive-autophagy.eu/
The manipulation of autophagy has a vast therapeutic potential to revolutionize the way cancers, neurodegenerative disorders, inflammatory diseases and infectious diseases are treated. Despite the promises made by pioneering medical studies, limited applied research on autophagy has hampered the translation of fundamental knowledge into clinical grade products and improved healthcare. Applied autophagy research is essential to understand the roles of autophagy in the different physiological and pathological situations, to generate (disease) models and develop biomarkers and assays to assess its progress. The goal of the ITN Driving next generation autophagy researchers towards translation (DRIVE) is to train 15 young scientists to fill this gap. DRIVE will equip its PhD students with a unique combination of knowledge and experimental expertise that are brought together in this consortium by the different partners. The realization of their projects in applied autophagy research will benefit from an exceptional interdisciplinary platform integrating cell biology, biochemistry, molecular biology, genetics, chemistry and “omics” approaches. In addition, DRIVE PhD students will acquire competencies to exploit the results for the development of products and techniques of commercial value.
Eligibility (who can apply): Early-Stage Researchers (ESRs).
Eligibility will be checked based on the following cumulative criteria:
a) Applicants Career Stage: Only Early Stage Researchers (ESR) can apply, that is, researchers of any nationality who, at the date of recruitment by the partner of DRIVE [1] have not yet been awarded a doctoral degree and [2] are in the first 4 years of his/her research career, counted from the date he/she obtained the degree (MSc degree or equivalent) that allows him/her to embark in a doctoral degree. Date of Recruitment means the first day of the employment of the researcher for the purposes of this project (i.e. the starting date indicated in the employment contract or equivalent direct contract).
b) Mobility: Applicants are required to undertake physical, transnational mobility (i.e. move from one country to another). That is, at the date of recruitment, the researcher must not have resided or carried out his/her main activity (work, studies, etc.) in the country of the partner of DRIVE he/she is applying for, for more than 12 months in the 3 years immediately prior to the his/her recruitment under the project. Compulsory national service, short stays such as holidays, and time spent as part of a procedure for obtaining refugee status under the Geneva Convention are not taken into account. For international European interest organisations or international organisations, recruited researchers must not have spent more than 12 months in the 3 years immediately before the recruitment date at the same appointing organisation.
IMPORTANTE NOTE: the career stage of eligible applicants and the mobility rule is determined in terms of fulltime research equivalent years. This means that research experience is measured from the date when a researcher obtained the degree which would formally entitle him/her to embark in a PhD degree, either in the country in which the degree was obtained or in the country in which the researcher is recruited, irrespective of whether or not a PhD degree is or was ever envisaged.
Application: Eligible candidates should fill in the application form and upload a cover letter stating their motivation and research interests, an updated CV with the dates of relevant diplomas (day, month and year), and the contact information of 2 referee persons, at https://drive-autophagy.eu/recruitment/
In case you wish to apply for the PhD student position available at the University of Turku, Finland (ESR3/UH), please indicate Prof. Eskelinen/ESR3 as the preferred research team within DRIVE’s network (see details below). You are welcome to indicate secondary and tertiary preference locations within the network in your application.
……………………………………………………………………………………………………………………………………………………………………….
Reference: ESR3/UH
Project Title: The role of RAB24 in healthy and diseased neurons
The goal in this project is to elucidate the physiological function of the small GTPase RAB24 in neuronal cells. We showed recently that RAB24 is required for the clearance of autolysosomes under nutrient-rich conditions (Ylä- Anttila et al. 2015, Autophagy 10:1833-48). This suggests that RAB24 is needed for basal autophagy, which is particularly important in postmitotic cells like neurons that are not able to dilute non-functional organelles and aggregate-prone proteins by cell division. Our results also showed that RAB24 facilitates the degradation of mutant huntingtin protein, which forms aggregates and causes the hereditary neurodegenerative Huntington’s disease. Others have revealed that huntingtin is normally degraded via autophagy. Importantly, mutations in RAB24 were shown to cause hereditary ataxia in dogs, due to loss of cerebellar Purkinje neurons because of defective autophagy (Agler et al, 2014, PLoS Genet 10, e1003991). These findings indicate that RAB24 is important for the neuronal survival and that RAB24 dysfunction causes disease.
To elucidate the physiological functions of RAB24 in neurons, the PhD student will investigate the effect of the disease-causing RAB24 mutation on both RAB24 function and autophagy in neuronal cells, using cell and molecular biological methodologies available on our laboratory and new assays that we will develop. In addition, the PhD student will search for RAB24 interacting proteins, and the most interesting hits in these screens will be verified in neuronal cell cultures and in mouse tissues. Co-immunoprecipitations and co-localization of
endogenous proteins in mouse tissues will be done in collaboration with the Boya laboratory. Finally, to elucidate in which regions of the central nervous system RAB24 is expressed and likely to play roles in neuronal survival, the PhD student will clarify the expression of RAB24 protein in the central nervous system of mice of different ages. More information about the host laboratory can be found athttp://www.helsinki.fi/autophagy.
5.11.2017 | Ajankohtaista
Medical Manager – AbbVie; Helsinki, Finland
Job description
AbbVie on maailmanlaajuinen, tutkimuslähtöinen biolääkealan yhtiö, joka aloitti toimintansa vuonna 2013 eriydyttyään Abbottista. AbbViessä yhdistyvät bioteknologia-alan yrityksen fokus sekä pitkään toimineen johtavan lääkealan yrityksen asiantuntemus. Yhtiön missiona on kehittää ja markkinoida kehittyneitä hoitoja hankaliin ja vakaviin sairauksiin asiantuntemuksensa, sitoutuneen henkilöstönsä ja innovaatiokykynsä avulla. Vuonna 2017 AbbVien henkilöstöön kuuluu noin 29 000 työntekijää ja yhtiö markkinoi lääkkeitä yli 175 maassa.
Suomessa AbbVie Oy on yksi Suomen parhaista työpaikoista. Organisaatiomme työllistää noin 85 ammattilaista Suomessa. Terapia-alueisiimme kuuluvat immunologia, onkologia, virologia ja neurologia. Työskentelemme matriisitiimeissä, joissa eri alueiden asiantuntijat toimivat yhteisen tavoitteen eteen. Haluamme, että kulttuurimme ja työilmapiirimme tukee työn iloa ja onnistumista sekä työn ja vapaa-ajan yhteensovittamista. Lue lisää meistä: www.abbvie.fi.
Haemme nyt Lääketieteelliselle osastollemme
Medical Manageria
vastaamaan immunologian terapia-alueen lääketieteellisestä työstä ja johtamaan neljän hengen asiantuntijatiimiä. Tiimin tehtävänä on tuottaa ja jakaa lääketieteellistä tietoa sekä antaa tieteellistä tukea sekä ulkoisille että sisäisille asiakkaille. Vastaat terapia-alueen lääketieteellisestä strategiasta sekä toimenpiteistä. Huolehdit, että kaikessa toiminnassa noudatetaan lakeja ja säädöksiä sekä sovittuja linjauksia. Varmistat, että sinulla ja tiimiläisilläsi on alan tuoreimmat tiedot seuraamalla tieteellisiä julkaisuja sekä osallistumalla kongresseihin. Luot ja ylläpidät hyviä suhteita tärkeimpiin asiakkaisiin sekä alan vaikuttajiin. Työskentelet tiiviissä yhteistyössä lääketieteellisen osaston kollegojesi, myynti- ja markkinointiosaston, kliinisen tutkimusosaston sekä Market Accessin kanssa. Raportoit tehtävässäsi Medical Directorille.
Odotamme sinulta monipuolista kokemusta ja näyttöä lääkealalta sekä jatkuvasti muuttuvan lääkealan ympäristön tuntemusta. Lisäksi tehtävä edellyttää lääketieteellistä, luonnontieteellistä tai muuta soveltuvaa ylempää korkeakoulututkintoa sekä vahvaa tieteellistä orientaatiota. Tieteellinen jatkokoulutus on tehtävässä eduksi, samoin immunologian terapia-alueen tuntemus. Esimiestyön ohella haluat kehittyä edelleen myös terapia-alueesi tieteellisenä asiantuntijana. Sinulla on erinomaiset vuorovaikutus- ja ihmisten johtamisen taidot sekä vahvat valmiudet luoda verkostoja ja toimia eri sidosryhmien kanssa.
Kommunikoit sujuvasti kirjallisesti ja suullisesti sekä suomeksi että englanniksi. Olet kiinnostunut työskentelemään kaupallisessa ympäristössä ja vaikuttamaan potilaiden hoitoon yhteistyössä alan asiantuntijoiden kanssa.Tarjoamme ainutlaatuisen näköalapaikan terveydenhuoltosektorilla osana menestyvää ja kasvavaa kansainvälistä yritystä sekä ympärillesi osaavan ja dynaamisen työyhteisön. Haluamme auttaa henkilöstöämme kehittymään niin, että he voivat hyödyntää potentiaalinsa parhaalla mahdollisella tavalla.
Kiinnostuitko? Lisätietoja tehtävästä antaa Medical Director Anne Lehtonen 7.11. klo 9–11 ja 8.11. klo 15–17, puh. 040 902 2397. Muina aikoina voit olla yhteydessä MPS-konsultti Nina Kalajokeen puh. 020 746 9413. Täytä hakemuslomake palkkatoiveineen ja liitä mukaan hakemuksesi sekä CV:si osoitteessa uratori.mps.fi 12.11.2017 mennessä.
4.11.2017 | Ajankohtaista
The Tumor Genomics Research Group at the University of Helsinki’s Faculty of Medicine, is one of the largest biomedical research groups in Finland with a 30-member research team, including biologists, computer scientists and medical doctors. The group focuses on understanding the causes and mechanisms of tumorigenesis, particularly in uterine leiomyoma and colorectal cancer. Here, researchers are given the opportunity to work in an internationally acclaimed research environment and good working atmosphere. The group offers the availability of state-of-the-art facilities, equipment, and bioinformatic resources for high-throughput analyses. The work has led to publications in journals such as Science, Nature, and New England Journal of Medicine.The group is part of the Academy of Finland funded Center of Excellence in Tumor Genetics (CoETG) with a special focus on understanding the interplay between genetic and environmental signals leading to neoplasia.
We are currently seeking outstanding candidates for
POST-DOCTORAL RESEARCHER AND GRADUATE STUDENT POSITIONS
The open positions are in the fields of cancer genetics, systems biology and bioinformatics research. We are looking for ambitious post-doctoral researchers and doctoral students with strong enthusiasm towards science. We expect the successful candidate to be highly self-motivated and responsible with excellent team working, problem solving, and analytical skills. The successful candidate has a strong background in medicine, genetics, molecular biology or bioinformatics (computer science, statistics or machine learning). Basic understanding of cancer biology and genetics/genomics is also considered important.
Post-doctoral responsibilities
Post-docs are expected to be able to conduct their research projects independently and coordinate collaborative projects effectively. The work includes student supervision as well as helping with administrative tasks.
Graduate student responsibilities
Graduate students are expected to conduct their given research project ambitiously, effectively and with attention to detail. Graduate students are encouraged to do team-work within the group. All graduate students will have supervision from Prof. Aaltonen and a post-doc member of staff.
We offer an initial contract of employment for a minimum period of two years. The position is a full-time position preferably starting in spring 2018. A trial period of four months will be applied. Salary is based on the University’s salary scheme for teaching and research personnel, composed of both task specific and personal performance components. The group is situated in Biomedicum, at the Meilahti Campus in Helsinki, Finland.
Closing date for applications is 30.11.2017.
3.11.2017 | Ajankohtaista
The Translational Cancer Faster Forward Doctoral Programme
“Educate tomorrow’s cancer researchers in a broad set of scientific, transferable, and business skills to become entrepreneurs”
The CanFaster program is supported by the European Union’s Marie Skłodowska-Curie programme, which is part of the Horizon 2020 framework and based on the ”Mobility across boarders” philosophy.
The CanFaster programme aims to attract excellent international PhD candidates with an interest in applied medical research in oncology and entrepreneurship to Lund University, CREATE health and Medicon Village.The program build on collaboration between industry, healthcare and academia to strengthen and accelerate innovations and clinical implementation in oncology. The 16 PhD students will gain an understanding of unmet needs in the clinic and learn the mind-set of entrepreneurs in an upcoming PhD programme within cancer.
16 international PhD student positions within Cancer and Entrepreneurship:
• Secondments in the non-academic sector, such as clinic or industry.
• Courses in Entrepreneurship, Innovation processes, Clinical aspects of cancer
• Seminar series at Lund University Cancer Center and SMILE Business Incubator
• Generous full-time salary; positions start Q1-Q2 2018.
Application deadline 17th of November 2017.
2.11.2017 | Ajankohtaista
https://www.embl.de/jobs/searchjobs/index.php?ref=EBI_01079
2.11.2017 | Ajankohtaista
A postdoctoral position is available immediately in the Neurobiology of Motivated Behavior Laboratory (NMBL) at McLean Hospital, Harvard Medical School. This position is funded to investigate the regulation and role of reward circuit glutamatergic signaling in prescription opioid addiction using rodent (rat) models.
The ideal candidate will be a recent Ph.D. graduate with a relevant background in Neuroscience as well as rodent behavior and stereotaxic surgery. Candidates who have a successful track record of procuring fellowships will be given priority. The candidate will be proposed for academic appointment as a Research Fellow in the Department of Psychiatry at Harvard Medical School. The initial appointment will be for two years with the possibility of extension. Salary will be commensurate with qualifications, laboratory experience, and institutional guidelines.
Please send application materials (CV and a brief summary of career goals and objectives) and a list of three professional references to:
Elena Chartoff, Ph.D.
Assistant Professor of Psychiatry and Neuroscience
Harvard Medical School
Director, Neurobiology of Motivated Behavior Laboratory
McLean Hospital
115 Mill Street
Belmont, MA 02478
Review of applications will begin immediately and continue until the position is filled.
2.11.2017 | Ajankohtaista
Cowin lab postdoc ad
31.10.2017 | Ajankohtaista
